Fish Oil Omega-3 - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The fish oil omega-3 market size stands at USD 1.19 billion in 2026 and is projected to reach USD 1.81 billion by 2031, translating into an 8.7% CAGR over the forecast period. This report is Segmented by Type (EPA, DHA), Species (Anchovy, Cod Liver, Salmon, Tuna, Other Species), Application (Dietary Supplements, Infant Nutrition, and More), End User (Adults, Geriatric, Children), and Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa). The Market Forecasts are Provided in Terms of Value (USD) and Volume (Tons).

Global Fish Oil Omega-3 Market Trends and Insights

Functional-food boom in EPA/DHA-fortified beverages

In a bid to navigate "softgel fatigue," global beverage giants are infusing EPA and DHA concentrates into their ready-to-drink dairy and plant-based offerings. These liquid formats not only boost bioavailability but also allow for smaller dosages without compromising on label claims, making them a convenient and efficient alternative to traditional supplements. Unilever's 2024 micro-encapsulation patents underscore a strategic push towards taste-masking, effectively eliminating the fishy aftertaste that has hindered widespread acceptance and paving the way for broader consumer adoption. By strategically placing these products in convenience retail outlets, brands are capitalizing on impulse buys, extending their reach beyond traditional pharmacy aisles, and tapping into a wider audience. With a focus on cognitive and cardiovascular benefits, these brands are successfully attracting non-supplement users, broadening the consumer base for the fish oil omega-3 market and driving growth in this segment. The United States Food and Drug Administration's approval of qualified health claims regarding the relationship between Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) consumption and the reduced risk of hypertension and coronary heart disease represents a pivotal shift in regulatory stance.

Prescription-grade EPA gaining cardiology guideline support

The American Heart Association recommended high-dose EPA for patients with triglycerides, even if they're on statins. This endorsement paves the way for icosapent ethyl to be recognized as a reimbursable therapy, leading to a notable shift of volumes from over-the-counter shelves directly into hospital formularies. When insurers make bulk purchases, it not only enhances price visibility for refiners but also prompts upgrades at refineries, focusing on achieving concentrates with ≥96% purity. With the European Society of Cardiology's endorsement anticipated in 2026, a similar trajectory is expected in Germany, France, and Italy, mirroring the U.S. trend. All these developments underscore the strengthening of prescription adoption, bolstering the clinical revenue stream for the fish oil omega-3 market.

Volatile Peruvian anchoveta biomass and quota suspensions

Late in 2023, El Niño events led to a significant decline in anchoveta recruitment, prompting quota suspensions that caused crude oil prices to surge by 34% in just two months. This disruption highlighted the vulnerability of the anchoveta supply chain to climatic events. While a 3 million-tonne quota set for the first half of 2025 indicates a recovery in biomass, ongoing trends of ocean warming pose a long-term threat to the stability and predictability of this supply. Pharmaceutical companies, which depend on consistent EPA/DHA inputs for their validated dossiers, face challenges as any variance in supply can disrupt production and regulatory compliance. Although there is a shift towards using Norwegian herring or Chilean jack mackerel as alternative sources, this approach merely transfers the ecosystem risk rather than resolving it. Consequently, the volatility of anchoveta continues to exert significant pressure on the fish oil omega-3 market in the short term, raising concerns about the sustainability of the supply chain.

Other drivers and restraints analyzed in the detailed report include:

• Emergence of supercritical co₂ purification hubs in South America
• Aquafeed reformulations to preserve omega-3 levels in salmon
• Surging microalgae capacity lowering entry barriers

Segment Analysis

With a projected CAGR of 10.04%, EPA-based ingredients are poised to outpace the broader fish oil omega-3 market, eclipsing the growth of DHA, even though DHA commands a dominant 63.42% revenue share in 2025. Hospitals and prescription channels are increasingly gravitating towards EPA concentrates with a purity of ≥96%. These premium concentrates, priced at about three to four times more than balanced EPA/DHA blends, are enabling an expansion in value capture, even if the volumes remain modest. To cater to these specialized demands, refiners are harnessing advanced chromatography columns and fractionation systems. These technologies adeptly segregate crude fish oil into distinct EPA-rich and DHA-rich streams, ensuring compliance with the varied pharmaceutical and nutritional regulations. While DHA maintains its supremacy in infant formulas and cognitive-health products like gummies, its growth trajectory is notably slower. This deceleration underscores a strategic shift towards the more lucrative therapeutic EPA within the fish oil omega-3 landscape. Collectively, this dual demand profile bolsters pricing power for specialty-grade outputs in contrast to their commodity-grade counterparts.

The shifting product landscape is sculpting unique supply-chain dynamics for both EPA and DHA. Pharmaceutical-grade EPA is mandated to traverse GMP-compliant facilities, adhering to stringent cleaning and documentation standards. In contrast, DHA supplements generally align with dietary and nutraceutical benchmarks. Processors adept in managing both streams enjoy a strategic advantage, allowing them to pivot capacity between wellness and clinical applications as market regulations and reimbursement avenues shift. Research and development efforts are increasingly focusing on EPA pro-drugs and advanced delivery mechanisms. These innovations promise heightened bioavailability and the potential to expand approved medical indications in the coming decade. Meanwhile, capital markets are showing a pronounced preference for companies boasting dual-stream capabilities and advanced purification technologies, perceiving them as prime candidates to harness the full spectrum of opportunities within the fish oil omega-3 market.

In 2025, anchovy-derived oils dominated the fish oil omega-3 market, capturing a 27.03% volume share. This dominance was driven by bountiful Peruvian harvests and well-established supply chains, which efficiently deliver cost-effective EPA/DHA concentrates for both supplements and aquaculture feeds. When sourced sustainably, these small pelagic fish yield high omega-3 levels with minimal contaminants. This quality supports a wide range of applications, from nutraceuticals to animal nutrition, even in the face of quota fluctuations in the South Pacific. While herring and jack mackerel offer additional volumes, they face challenges with tightening quotas in the North Sea and Pacific. This dynamic reinforces the anchovy's stable baseline. In Norway, producers not only rely on wild catches but also refine salmon processing trimmings into low-contaminant oils. These oils, certified by MSC and Friends of the Sea, command sustainability premiums, helping to buffer revenue volatility. This diverse species mix guarantees a consistent throughput, even amidst the unpredictable nature of fishery yields.

Salmon oils are on a rapid ascent, with projections indicating a 9.51% CAGR growth rate through 2031. This surge is largely attributed to advancements in aquaculture, which are refining feed formulations and boosting the omega-3 content in farmed salmon fillets. Norwegian operations are turning salmon viscera by-products into premium concentrates. By leveraging dual certifications, they not only command elevated prices but also seamlessly integrate into retail marketing, positioning their salmon as a direct health benefit due to its high omega-3 content. This vertical integration fosters unique synergies: heightened demand for salmon fillets amplifies the availability of by-products, and the reverse is equally true. Such dynamics solidify salmon's pivotal role in the fish oil omega-3 value chain. Refiners are capitalizing on this trend, achieving monetization across multiple products and balancing the inherent risks of wild captures with the stability of farmed supplies. The overall trajectory highlights salmon's escalating significance in addressing the world's growing appetite for omega-3s.

Complete Report Scope:

• By Type
  • EPA (Eicosapentaenoic Acid)
  • DHA (Docosahexaenoic Acid)
• By Species
  • Anchovy
  • Cod Liver
  • Salmon
  • Tuna
  • Other Species
• By Application
  • Dietary Supplements
    • Congnitive Health
    • Heart Health
    • Other Health Applications
  • Infant Nutrition
  • Functional Food and Beverage
  • Other Applications
• By End User
  • Adults
  • Geriatric
  • Children
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Russia
    • Netherlands
    • Poland
    • Belgium
    • Sweden
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Singapore
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • Egypt
    • Morocco
    • Turkey
    • South Africa
    • Rest of Middle East and Africa

Geography Analysis

In 2025, Medicare Part D's reimbursement of icosapent ethyl helped North America secure 34.10% of the revenue. IMS Health highlighted this momentum, noting a robust 47% year-over-year growth with 2.3 million prescriptions recorded in Q4 2025. While Canada's over-the-counter market and Mexico's fortified-food initiatives bolster demand, the U.S. shines brightest, thanks to its advanced clinical infrastructure, which supports the development and distribution of high-quality omega-3 products. As generics enter the fray, competition heats up, leading to price pressures and increased innovation among manufacturers. Yet, premium formulations, endorsed by GOED and MSC seals, maintain a pricing advantage due to their superior quality and certifications, solidifying North America's dominance and profitability in the fish oil omega-3 market.

Asia-Pacific is poised to take the lead, eyeing a projected 10.80% CAGR through 2031. China's SAMR aligns contaminant limits with EU standards, guiding imports towards purer oils and ensuring compliance with stringent quality benchmarks. Japan's FOSHU initiative, championing EPA/DHA health benefits, and its aging demographic, ensure consistent demand, as older populations increasingly seek health supplements. In India, the integration of omega-3s into staple edible oils expands market reach, catering to a growing health-conscious consumer base. E-commerce platforms like Tmall and Rakuten are reshaping direct-to-consumer sales, allowing smaller global brands to access vast audiences without the overhead of physical stores, thereby democratizing market entry and fostering competition.

Germany, the UK, and Scandinavia, known for their supplement-centric cultures, anchor Europe's robust presence in the industry. These regions have a long-standing tradition of prioritizing health and wellness, which drives the demand for dietary supplements. Despite navigating stringent regulations, including compliance with the European Food Safety Authority (EFSA) standards, and championing sustainability through eco-friendly practices and packaging, Europe continues to assert its dominance in the global market. With the European Food Safety Authority at the helm, the region is making strides in global novel food approvals and safety evaluations. Norway reaps rewards from its integrated approach, merging herring catches with salmon processing and top-tier purification. Though Southern Europe trails in per-capita consumption, there's a noticeable uptick, especially with functional drinks targeting heart health. Overall, Europe's regulatory landscape solidifies its role as a cornerstone in the global fish oil omega-3 market.

List of Companies Covered in this Report:

• DSM-Firmenich
• BASF SE
• Croda International plc
• Omega Protein Corporation
• Corbion NV
• GC Rieber VivoMega
• Pelagia AS
• TripleNine Group A/S
• TASA (Tecnologica de Alimentos S.A.)
• Austevoll Seafood ASA
• Olvea Group
• Lysi hf
• Barleans Organic Oils
• Nordic Naturals, Inc.
• Cargill Inc. (EWOS)
• AlaskOmega (OmegaSea, LLC)
• Kobyalar Group
• Copeinca ASA
• Solutex GC
• Evonik Industries
• Golden Omega SA

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support